Jochen Klaus

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

Brian G. Feagan, Bruce E. Sands, William J. Sandborn et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 208 citations

Systemic Treatment, Golimumab Monotherapy, Gastroenterology +4

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study

William J. Sandborn, Scott D. Lee, Dino Tarabar et al. · Gut · 2017 · 107 citations · Full text

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Laurent Peyrin‐Biroulet, Ailsa Hart, Peter Bossuyt et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 89 citations · Full text

Inflammation, Anti-inflammatory, Immunology +7

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Laurent Peyrin‐Biroulet, Jessica R. Allegretti, David T. Rubin et al. · Gastroenterology · 2023 · 86 citations · Full text

Small intestinal bacterial overgrowth mimicking acute flare as a pitfall in patients with Crohn's Disease

Jochen Klaus, Ulrike Spaniol, Guido Adler et al. · BMC Gastroenterology · 2009 · 80 citations · Full text